Anna Näger is currently a Clinical Research Associate II at ICON plc since August 2025, with prior experience that includes a range of research positions and clinical roles. Anna's research background features internships at Academia Sinica and the Technical University of Munich, focusing on peptide therapy for prion diseases and adoptive T-cell therapy for chronic HBV infection, respectively. A PhD in Molecular Life Sciences was earned at EPFL, emphasizing human telomeres and associated genomic stability research. Previous clinical experiences include positions at IQVIA as a Clinical Research Trainee and Clinical Research Associate I, where responsibilities included site management, trial monitoring, and ensuring compliance with regulatory requirements. Academic qualifications encompass a Master of Science in Molecular Biotechnology and a Bachelor of Science in Molecular Biotechnology from the Technical University of Munich, complemented by a brief academic engagement at the National University of Singapore.
This person is not in the org chart
This person is not in any teams
This person is not in any offices